CY1120921T1 - Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες - Google Patents

Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες

Info

Publication number
CY1120921T1
CY1120921T1 CY181100982T CY181100982T CY1120921T1 CY 1120921 T1 CY1120921 T1 CY 1120921T1 CY 181100982 T CY181100982 T CY 181100982T CY 181100982 T CY181100982 T CY 181100982T CY 1120921 T1 CY1120921 T1 CY 1120921T1
Authority
CY
Cyprus
Prior art keywords
ceremonies
soluble polymers
low grade
grade water
modified blood
Prior art date
Application number
CY181100982T
Other languages
Greek (el)
English (en)
Inventor
Peter Turecek
Juergen Siekmann
Hanspeter Rottensteiner
Original Assignee
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH filed Critical Baxalta GmbH
Publication of CY1120921T1 publication Critical patent/CY1120921T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY181100982T 2008-10-17 2018-09-24 Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες CY1120921T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10642408P 2008-10-17 2008-10-17
PCT/US2009/061023 WO2010045568A1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer

Publications (1)

Publication Number Publication Date
CY1120921T1 true CY1120921T1 (el) 2019-12-11

Family

ID=41650072

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100982T CY1120921T1 (el) 2008-10-17 2018-09-24 Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες

Country Status (20)

Country Link
US (4) US20100099616A1 (enExample)
EP (3) EP3437661A1 (enExample)
JP (2) JP5785872B2 (enExample)
KR (2) KR101929641B1 (enExample)
AU (1) AU2009305612B2 (enExample)
BR (1) BRPI0920259A8 (enExample)
CA (1) CA2738679A1 (enExample)
CY (1) CY1120921T1 (enExample)
DK (1) DK2349342T3 (enExample)
ES (1) ES2692172T3 (enExample)
HR (1) HRP20181454T1 (enExample)
HU (1) HUE039906T2 (enExample)
LT (1) LT2349342T (enExample)
MX (1) MX2011004085A (enExample)
NZ (1) NZ592688A (enExample)
PL (1) PL2349342T3 (enExample)
PT (1) PT2349342T (enExample)
SI (1) SI2349342T1 (enExample)
SM (1) SMT201800486T1 (enExample)
WO (1) WO2010045568A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US20130183280A1 (en) * 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
GB201910190D0 (en) * 2012-04-16 2019-08-28 Cantab Biopharmaceuticals Patents Ltd Optimised subsutaneous therapeutic agents
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
BR0311978A (pt) * 2002-06-21 2005-03-22 Novo Nordisk Healthcare Ag Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
MXPA05006688A (es) 2002-12-19 2006-02-22 Nektar Therapeutics Al Corp Conjugados de polimero con una variante de cianovirina.
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
JP2006523211A (ja) * 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
AU2007333049B2 (en) * 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.

Also Published As

Publication number Publication date
AU2009305612A1 (en) 2010-04-22
KR20160103173A (ko) 2016-08-31
ES2692172T3 (es) 2018-11-30
PT2349342T (pt) 2018-10-26
CA2738679A1 (en) 2010-04-22
HUE039906T2 (hu) 2019-02-28
HRP20181454T1 (hr) 2018-12-14
EP2349342B1 (en) 2018-06-27
KR20110071012A (ko) 2011-06-27
SMT201800486T1 (it) 2018-11-09
EP2349342A1 (en) 2011-08-03
US20120076749A1 (en) 2012-03-29
BRPI0920259A8 (pt) 2017-09-19
KR101929641B1 (ko) 2018-12-14
US20160199503A1 (en) 2016-07-14
WO2010045568A1 (en) 2010-04-22
EP3437661A1 (en) 2019-02-06
JP2012505917A (ja) 2012-03-08
EP3620177A1 (en) 2020-03-11
MX2011004085A (es) 2011-09-27
NZ592688A (en) 2012-12-21
DK2349342T3 (en) 2018-10-08
BRPI0920259A2 (pt) 2016-01-05
PL2349342T3 (pl) 2019-01-31
LT2349342T (lt) 2018-10-10
JP5785872B2 (ja) 2015-09-30
US20190160178A1 (en) 2019-05-30
AU2009305612B2 (en) 2015-05-21
SI2349342T1 (sl) 2018-10-30
US20100099616A1 (en) 2010-04-22
JP2015110676A (ja) 2015-06-18

Similar Documents

Publication Publication Date Title
CY1123684T1 (el) Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
CY1122636T1 (el) Συνθεσεις για τη συνδεση στοιχειων με δακτυλους ψευδαργυρου
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1118472T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
CY1121134T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης
ATE541597T1 (de) Implantierbare vorrichtung mit sich langsam auflösendem polymer
DE602007009388D1 (de) Implantierbare medizinprodukte aus verzweigten polymeren
EA201170038A1 (ru) Загруженные лекарственным средством полимерные наночастицы и способы их получения и применения
BR112012028977A2 (pt) polímero estímulo- responsivo para purificação de biomoléculas.
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
EP2399940A3 (en) Modified macromolecules and methods of making and using thereof
EA201290497A1 (ru) Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
CY1116590T1 (el) Υλικα πολυ οξο-υδροξυ μεταλλικου ιοντος τροποποιημενα με εκλεκτικο συνδετη, χρησεις αυτων και μεθοδοι παρασκευης αυτων
ECSP099684A (es) Aril pirrolidinas insecticidas
ATE554978T1 (de) Überwachungseinrichtung zur überwachung von systemen eines fahrzeugs
WO2013101902A3 (en) Chromophoric polymer dots with narrow-band emission
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1112469T1 (el) Μια il-2 μουτεϊνη για θεραπεια ή για προφυλαξη απο ενα αυτοανοσο νοσημα
CO6620039A2 (es) Composiciones de catalizador para producir poliolefinas de alt mz/mw
BRPI0922382A2 (pt) "material de polímero à base de celulose".
CY1108829T1 (el) Ενεργοποιηση ace2 για θεραπεια καρδιακης, πνευμονικης και νεφρικης ασθενειας και υπερτασης
BR112013015885A2 (pt) composição de procatalisador, composição de catalisador e composição polimérica.